Through analysis of ES transcriptomic data from the R2: Genomics Analysis and Visualization Platform, it was found that higher PAK1 and PAK4 expression levels were associated with metastatic disease and worse patient outcome, while patients with localized disease demonstrated lower levels of PAK1 and PAK4 expression [2]. This evidence concerns the gene PAK4 and metastatic neoplasm.